Stanford AI designs 16 working bacteriophages
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Stanford's Brian Hie used generative AI models Evo1 and Evo2 to design 16 novel bacteriophages that killed E. coli — the first whole genomes written by AI that actually function in a lab.link ›
- Of 302 AI-designed candidates synthesized, just 16 worked; the working phage genome is roughly 5,400 base pairs versus 500,000 for the smallest living cell and 3 billion for humans.link ›
- Johns Hopkins's Thomas Inglesby and Moritz Hanke warned the work raises 'urgent biosafety and biosecurity questions' about viruses with disease potential.link ›
- FDA granted accelerated approval to Replimune's RP1, now Tudriqev, for advanced melanoma at a $450,000 list price after two prior rejections and a recent advisory panel vote in favor.link ›
- NYU Langone's Josef Coresh led an ARIC analysis of 12,409 adults finding those without high blood pressure, diabetes, or smoking averaged 30.1 dementia-free years versus ~17 for those with all three.link ›
- Seoul National University's Eun Bong Lee tracked 1,070 rheumatoid arthritis patients across 12,583 visits over four years and tied PM2.5 exposure to flare risk after two or more weeks.link ›
- Medicare's ACCESS model has been pushing enrollment for about one month without telling beneficiaries which providers participate.link ›
Stanford researchers used generative AI models Evo1 and Evo2 — trained on genetic code from viruses, bacteria, plants, and people — to design 16 novel bacteriophages that killed E. coli. Of 302 candidates synthesized, just 16 worked, but Brian Hie called it a leap in 'complexity that's designable by generative AI': the first whole genomes written by a machine that actually function. The phage genome is roughly 5,400 base pairs — a rounding error next to the smallest living cell at 500,000 — and Johns Hopkins's Thomas Inglesby and Moritz Hanke immediately warned of 'urgent biosafety and biosecurity questions' about viruses with disease potential. The FDA gave Replimune's Tudriqev accelerated approval for advanced melanoma at a $450,000 list price after two prior rejections. The oncology pipeline runs on bureaucratic pace; the genome-design pipeline does not.
The stories behind this week
AI Designs 16 New Functional Viruses in Lab FirstThe 16 successful bacteriophages mark the first AI-written genomes to function in a lab, a stepping stone toward AI-designed living organisms (the smallest cell genome is roughly 100× larger than the phage's). The same capability that promises phage therapies for antibiotic-resistant infections also gives regulators a concrete example — not a thought experiment — of why biosecurity guardrails must catch up before the technology scales.
Study finds three midlife health factors that could delay dementia for 13 yearsThis study shifts dementia-prevention messaging from vague 'live healthy' advice to three concrete midlife targets: blood pressure, blood sugar, and smoking. The buried racial and gender gaps in dementia-free years indicate that even people who manage vascular risks face unequal outcomes that public health responses have yet to address.
Microbiome Forensics Faces Real-World LimitsFor investigators facing cases with no DNA or fingerprints, microbial community profiling could provide actionable leads despite not meeting the statistical certainty of human DNA—shifting the standard from proof to probabilistic intelligence when traditional methods fail. This changes how evidence is weighted in cold cases, particularly where soft-tissue trauma erases conventional traces.
Dirty air may trigger painful rheumatoid arthritis flaresWith RA affecting an estimated 0.5% to 1% of adults worldwide, the study adds PM2.5 to smoking as a potentially modifiable RA trigger. For clinicians, the practical implication is concrete: advising RA patients to limit outdoor time during high-PM2.5 periods may now sit alongside medication adherence as a standard disease-management tool.
FDA Approves Replimune’s Melanoma Drug TudriqevPatients gain access to a new melanoma therapy after repeated rejections, while Replimune avoids a potential setback that could have derailed its future; the $450,000 price tag underscores ongoing pressure on payers for high-cost oncology drugs with marginal trial data.
Medicare Pushes ACCESS Without Provider DirectoryIf Medicare steers beneficiaries toward ACCESS without disclosing participating providers, patients can't verify whether their preferred doctors are in the program before enrolling—undermining informed choice in a model explicitly designed to expand access. The mismatch between promotional push and directory disclosure hits hardest for the dual-eligible and complex-care populations ACCESS targets.
Peter Bond's Out of This World: an astronaut historyThe reviewer explicitly flags Bond's near-total omission of debates over colonising the Moon and Mars for private and national profit — a notable gap given that NASA's Artemis mission has been partially restructured even as the book went to print, leaving readers without the political-economy framework that now defines the next lunar push.
Why dogs ignore low-flying planes: readers weigh inThe exchange shows how a casual observation about animal behavior yields competing explanations — evolutionary (no aerial threat) versus experiential (Silvester's roof-skylight anecdote) — with the spaniel reply demonstrating that at least some dogs do react to overhead movement, undermining any blanket claim that the species ignores the sky.
Why it matters: When Stanford proved generative AI can write a working 5,400-base-pair viral genome, the biosecurity debate stopped being hypothetical — the question is now how fast a framework can be written before someone points the same pipeline at something worse than E. coli.
